Alkermes (ALKS) Q2 2026: Revenue Surges but EPS Hits Zero
As seen on the 24/7 Wall St. homepage on July 28, 2026.
Alkermes blew past revenue expectations as the Avadel acquisition kicked in with LUMRYZ contributing $96.6 million, but earnings cratered to zero on acquisition charges and $26.4 million in contingent consideration step-ups. The company also announced CEO Richard Pops is handing the reins to Blair Jackson effective August 1.
Continue ReadingShow less
Alkermes posted Q2 2026 revenue of $496 million, beating the $457.4 million analyst estimate by roughly 8.5% and marking a sharp jump from the $390.7 million reported in the same quarter a year earlier. The standout driver was LUMRYZ, the narcolepsy treatment acquired through the Avadel deal, which contributed $96.6 million to the top line on its own.
Despite the revenue beat, earnings per share came in at zero against an estimated $0.29, a 100% miss. The shortfall was not an operational stumble but rather the accounting cost of the acquisition itself — charges tied to the deal combined with $26.4 million in contingent consideration step-ups wiped out the quarter's profit entirely. Investors watching the stock will need to separate those one-time items from the underlying business momentum when assessing the quarter's true health.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The quarter also brought a leadership change: longtime CEO Richard Pops is passing the role to Blair Jackson, with the transition effective August 1. Pops has led Alkermes for decades, so the handover represents a meaningful shift in the company's direction at a moment when the Avadel integration is still in its early stages.
Mentioned: ALKS